Mitchell & Pahl Private Wealth LLC Buys 4,881 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Mitchell & Pahl Private Wealth LLC lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 12.6% during the fourth quarter, HoldingsChannel reports. The firm owned 43,728 shares of the company’s stock after acquiring an additional 4,881 shares during the quarter. Mitchell & Pahl Private Wealth LLC’s holdings in Elanco Animal Health were worth $530,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ELAN. Benjamin F. Edwards & Company Inc. raised its stake in Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC bought a new stake in Elanco Animal Health in the 3rd quarter valued at $29,000. AM Squared Ltd bought a new stake in Elanco Animal Health in the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB bought a new stake in Elanco Animal Health in the 3rd quarter valued at $35,000. Finally, Quarry LP acquired a new position in Elanco Animal Health in the 2nd quarter valued at $40,000. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ELAN. Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Barclays upped their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $16.43.

Elanco Animal Health Stock Performance

ELAN opened at $12.04 on Wednesday. The firm has a market cap of $5.95 billion, a P/E ratio of 30.09, a price-to-earnings-growth ratio of 2.56 and a beta of 1.41. Elanco Animal Health Incorporated has a 52-week low of $11.11 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business’s fifty day moving average is $12.43 and its 200-day moving average is $13.32.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.18 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.